Looking for the needle: Glycopepetide Resistance in Staphylococcus aureus
|
|
- Megan Bond
- 5 years ago
- Views:
Transcription
1 Looking for the needle: Glycopepetide Resistance in Staphylococcus aureus
2 SA Resistance Penicillin: 1940s, R by 60% Streptomycin: Late 1940s, R developed rapidly Tetracycline: Late 1940s, R after 4yrs Erythromycin: 1952, R developed rapidly By late 1950 s s Multiple R SA Chloramphenicol: Late 1950s, 34% R after 2 years Methicillin: 1960s, 1% by 1970, 42% by 2006 but down to 35% in 2007
3 MRSA Rates
4 Emergence of Vancomycin Resistance Vancomycin introduced in 1950s 1980s increase in use In-vitro R: 1956 study testing activity of new antimicrobials 1990s Daum et al 4 to 8 and 8 to 16 fold increases in MIC seen in 2 strains Biavasco et al - Vanc MICs rose from 2 to 8 in 4 SA strains in single-step step No of strains MIC mg/l 1 2 Vancomycin Initial MIC mg/l No of Transfers Final MIC mg/l Vancomycin (6) (1) 16 (5)
5 Introduced around 1990 Teicoplanin More lipophilic,, better penetration into tissues, phagocyte Can be given I.M. Lower toxicity Early clinical studies showed high failure rate Higher doses used R in-vitro to T achieved more readily than to V Single step fold increase in MIC T Resistance to in SA unknown R found in early 1990s Confusion with V R Rates in 13% UK, >30% France
6 In-vivo Resistance: GISA Location, Strain name, ref. Japan. (Mu50, Hiramatsu, et al., 1997) Limoges, France. (LIM2, 3, Ploy et al., 1999) Michigan, USA. (MI, Smith et al., 1999) New Jersey, USA. (NJ, Smith et al., 1999) Edinburgh, Scotland. (Glasgow 3700 and 3759, Patron et al., 2001) Patient Details Underlying Conditions GISA Prior Vanc Therapy Infection Outcome 4m, Male Post surgery 41 days Sternal wound infection Recovered with ARB+AMP/SUL 2y, Female Leukaemia 10 days CVC-associated bacteraemia 59y, Male DM, ESRD, Ca 18 weeks CAPD peritonitis 66y, Male DM 18 weeks Bacteraemia Recovered with drainage + 10 days Q/D Recovered from peritonitis, died from un-related cause. Recovered from bacteraemia, died from un-related cause. ND Post surgery 20 days ND ND Illinois (St Luke, MMWR, 1999) 63y, female ESRD 25 days Mitral valve endocarditis Minnesota, USA (Fridkin, 2001) 56y, ESRD 18 weeks Vertebral osteomyelitis Los Angeles, USA (Hageman, et al., 2001, Marlowe et al., 2001) Seoul, Korea (Kim et al., 2000) 45y, male metastatic Ca New York, USA (Rotun, et al., 1999, Sieradski et al., 1999) Germany (Anonymous, 1998) Brussels, Belgium (Denis et al., 2000) Brazil (Oliveira, et al., 2001) 27y, female ND 10 weeks Cholangitis 8 days, + 30 days teicoplanin MRSA bacteraemia Died of infection despite VAN + RIF + TOB Infection cleared with VAN+NAF+GEN, but patient died Infection cleared with LIN+TMP/SMX+DOX Died after 2 weeks of VAN+CIP+MTZ 79y, male ESRD 44 days CVC-associated bacteraemia Died of infection 2 patients 1 patient 1 patient 1 patient 1 patient 8y, male 1.5y, male 11y, female 26y female 39y, female post surgery on ITU ND Cystic fibrosis ITU ITU Burns Burns Burns ITU patient Burns ND ND ND ND ND 39 days 32 days 31 days 67 days 74 days Wound sepsis Infection at CVC site Colonising respiratory tract Colonising decubitus ulcer Colonising Colonising Colonising infection not specified infection not specified Both recovered with glycopeptide therapy Resolved without specific therapy ND ND ND Recovered Recovered Recovered Recovered with TMP/SMX Died
7 In-vivo Resistance: hgisa Location, Strain name, ref. Japan. (Mu3, Hiramatsu, et al., 1997) Bristol, UK. (SMH2, Howe, et al., 1999) Patient Details Underlying Conditions hgisa Prior Vanc Therapy Infection 64y, Male Post surgery for lung Ca 12 days MRSA pneumonia 82y, Male ESRD CVC-related bacteraemia Germany (Witte, 2001) 43y, male Alcoholic Nosocomial pneumonia Lyon, France (Bobin-Dubreaux et al., 2001) Hong Kong (Wong et al., 1999) Australia (Ward, et al., 2001) Thailand (Trakulsomboon, et al 2001) Genoa, Italy (Marchese, et al., 2000) Sydney, Australia (Gosbell et al., 2003) Poland (Krzyszton-Russjan et al, 2002) San Francisco, USA (Moore et al., 2003) Outcome Recovered with AMP/SUL + ARB Died of infection after 21 days of VAN No response to 11 days VAN or Q/D. Responded to LIN. 35y, female Nil Nil Conjunctivitis Responded to topical TOB 16 patients 41y, male 68y, female 16y, female 61y, male 62y 58y range from renal failure to lung Ca ESRD, DM, Post bilateral lower limb amputation DM, post knee replacement Nil DM, hepatic cirrhosis Post-pancreas transplant Post lung Ca surgery range from neutropenic sepsis to catheter colonisation 57 days surgical site infection 75 days 14 days Nil 15 days 79y, male Mitral-valve annuloplasty 14 days 45y, male Stomach Ca 41 days, V+21 days T 47y, male IV drug use Nil Surgical site infection Retroperitoneal infection Nosocomial pneumonia Isolated from drainage fluid Chest infection Post operative MRSA bacteraemia+endocarditis ND Community acquired endocarditis, osteomylitis 9 patients Died, others recovered after removal of catheter. No response to 73 days of glycopeptide, resolved with LIN Died Recovered Died Recovered on VAN+CAZ+TMP/SMZ Died Died from pneumonia caused by EC Responded to Q/D treatment Responded to two 6 week courses of V+RIF
8 Vancomycin Non-Susceptible Rates
9 2002, Michigan Emergence of VRSA 40yr Female with hypertension, diabetes mellitus, peripheralvascular disease and chronic renal failure plus haemodialysis Multiple courses of antimicrobial Tx including V Recurrent foot ulcers, metatarsal amputation followed by bacteriaemia Arteriovenous graft for dialysis access replaced by catheter After 6 wks V Tx catheter tip culture positive for MRSA and VRE. MRSA V MIC = 1024mg/L
10 10 reported VRSA Michigan, US (2 clonal types) Pennsylvania, US 2004/7-2 New York, US Iran, 1 Bengal, V MICs = 512mg/L vana Patients: History of MRSA infection or colonisation Several underlying conditions Most received V Tx but not all Patient to patient transfer was ruled out in Michigan
11 V Therapy Failure Clinical Relevance Common - 20% failure in MRSA endocarditis, 40% in LRTI Due to Poor tissue penetration, Slow bactericidal activity or Higher MICs? GISA/hGISA vs. Outcome 226 bacteriaemia cases: Duration of bacteriaemia,, V Tx,, failure to remove source predictors of Tx failure Common factors: underlying disease, medical device, prolonged V Tx Bacteriaemia: : Patients with hgisa are more likely to have high bacterial load, V Tx failure and bacteriaemia >7d (2004) MIC 1 1 : significant risk of vancomycin treatment failure in MRSA bacteriaemia (2004) AUC correlate with failure of V Tx in bacteriaemia (2007) Johnson et al 2003, Scan J Inf Dis 35:782-9 Neoh et al 2007, An Clin Microb Antimicrob 6:13 Charles et al 2004, Clin Inf Dis 38:
12 Clinical Relevance In-vivo/vitro models 2 SA strains in rabbit model: Eradication of pre V Tx strain faster than post Pharmacodynamic model: Mu50 eradicated at same rate as GSSA Outbreaks Perpignan (1999): 12 hgisa, 3 clonal types, no V Tx >3% of MRSA Liverpool 1991:? Patients, 25 strains, same clone Southhampton : 75 teicoplanin R SA T 8mg/L, V 2-4mg/L2 EMRSA 17 Treated successfully with V
13 Resistance Mechanism Scarcity of strains: strain specific traits V Mode of action: Inhibit cell wall synthesis, alter cell membrane permeability and selective inhibition of RNA synthesis Peptidoglycan synthesis:
14 Resistance Mechanism Target D-alaD ala-d-ala 1. Completed PG chain 2. Nascent PG chain 3. Murein monomers in cytoplasmic membrane 1 & 2 - Reduces cross links 3 - Inhibits cell wall synthesis GSSA 20 PG layers hgisa/gisa PG layers
15 GISA Characteristics or Strain Specific Traits Increased PG biosynthesis? PBP2 increase: Found in Mu50/Mu3, results contradictory PBP4 decrease: Found in some GISA/hGISA strains but not others. Less cross links more targets for V GlmS increased activity: Found in Mu50 and Mu3, results unsubstantiated Expression studies No evidence of increased production of PG biosynthesis enzymes
16 GISA Characteristics or Strain Specific Traits Decreased Cell Wall Turnover? Autolysin Atl expression decreased: Found in most GISA/hGISA Reduced Triton induced autolysis rates: All GISA/hGISA except Mu50 & Mu3 No promoter mutation expression reduced
17 GISA Characteristics or Strain Specific Traits No atl promoter mutations Accessory gene regulator (agr( agr) ) defects in some In-vitro mutants and in some GISA/hGISA does not regulate atl expression and not a requirement of GISA/hGISA Other regulators: lytsr, lrgab, arlrs Micro array: contradictory results Mutated grar in Mu50: increased resistance in Mu3 to GISA
18 Mechanism summary Probably decreased cell wall turnover Resistance achieved by different routes Multi step alterations / mutations required for intermediate resistance Mu50 & Mu3 genetically distinct acquired resistance by different route than others in same clonal type
19 Detection Breakpoints: BSAC: V and T 8 / 8 / 4 CLSI (pre 2006): 32 / / 4 CLSI (post 2006): 16 / / 2 GRSA GISA hgisa Typical V MIC > Sakoulas: MIC 1mg/L = V Tx failure Neoh: : AUC correlates to clinical outcome Outcome MIC AUC D to afebrile Poor ± Good ± Sakoulas et al 2004, J Clin Micro 42: Neoh et al 2007, An Clin Microb Antimicrob 6:13
20 Detection in US Breakpoints CLSI (post 2006): 16 / / 2 >300,000 SA from US & Europe
Evolution of antibiotic resistance. October 10, 2005
Evolution of antibiotic resistance October 10, 2005 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationPrescot Street, Liverpool, Merseyside L7 8XP, UK. Street, Liverpool, Merseyside L7 8XP, UK
Journal of Medical Microbiology (2009), 58, 376 380 DOI 10.1099/jmm.0.006486-0 Case Report Correspondence Andrew Kirby amk@liv.ac.uk In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationThe new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining?
S. aureus: what do we need to know (and to do) in 2007? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? Françoise Van Bambeke Unité de Pharmacologie
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationCombating antibiotic resistance. October 23, 2006
Combating antibiotic resistance October 23, 2006 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart diseases:
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationCHAPTER 1 INTRODUCTION
1 CHAPTER 1 INTRODUCTION The Staphylococci are a group of Gram-positive bacteria, 14 species are known to cause human infections but the vast majority of infections are caused by only three of them. They
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationHOW TO INTERPRET CULTURE RESULTS. Karen Brust, MD November 29, 2012
HOW TO INTERPRET CULTURE RESULTS Karen Brust, MD November 29, 2012 DISCLOSURES NONE CULTURE RESULTS Based on susceptibility patterns CLSI: international, interdisciplinary, Nonprofit,
More informationGuidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK
Journal of Antimicrobial Chemotherapy Advance Access published February 27, 2006 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkl017 Guidelines for the prophylaxis and treatment of methicillin-resistant
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationIs Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5122 5126 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.00485-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Is Cefazolin
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationMicrobiology ( Bacteriology) sheet # 7
Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationStaphylococcus aureus and Health Care associated Infections
Staphylococcus aureus and Health Care associated Infections Common - but poorly measured Prof Peter Collignon The Canberra Hospital Australian National University What are health-care associated infections?
More informationIn vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationPATIENT DEMOGRAPHICS. Surname. Given name. Pacific Islander (non-maori) ADMISSION DETAILS
Reviewer / hospital Date review started PATIENT DEMOGRAPHICS MRN DOB Sex Patient sticky label if available, else enter details here Surname Post-code Given name Australian Aborigine / TSI Middle Eastern
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationEmpiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital
Original Article Brunei Int Med J. 2013; 9 (6): 372-377 Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital Lah Kheng CHUA, Department of Pharmacy, RIPAS Hospital,
More informationQ1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.
Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationIn-Service Training Program. Managing Drug-Resistant Organisms in Long-Term Care
In-Service Training Program Managing Drug-Resistant Organisms in Long-Term Care OBJECTIVES 1. Define the term antibiotic resistance. 2. Explain the difference between colonization and infection. 3. Identify
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationEmpiric therapy for severe suspected Staphylococcus aureus infection
Empiric therapy for severe suspected Staphylococcus aureus infection Salman Qureshi, MD McGill University Faculty of Medicine Department of Critical Care Medicine McGill University Health Centre Relevant
More informationESCMID Online Lecture Library. by author
ESCMID Postgraduate Technical Workshop Antimicrobial susceptibility testing and surveillance of resistance in Gram-positive cocci: laboratory to clinic Current epidemiology of invasive enterococci in Europe
More informationMicrobiological Surveillance of Methicillin Resistant Staphylococcus aureus (MRSA) in Belgian Hospitals in 2003
Microbiological Surveillance of Methicillin Resistant Staphylococcus aureus (MRSA) in Belgian Hospitals in 3 Final report Olivier Denis and Marc J. Struelens Reference Laboratory for Staphylococci Department
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationCombating antibiotic resistance
Combating antibiotic resistance October 8, 2007 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart diseases:
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationMeropenem for all? Midge Asogan ICU Fellow (also ID AT)
Meropenem for all? Midge Asogan ICU Fellow (also ID AT) Infections Common reason for presentation to ICU Community acquired - vs nosocomial - new infection acquired within hospital environment Treatment
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationHISTORY AND EPIDEMIOLOGY...105
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2010, p. 99 139 Vol. 23, No. 1 0893-8512/10/$12.00 doi:10.1128/cmr.00042-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Reduced Vancomycin
More informationBeta-lactam antibiotics - Cephalosporins
Beta-lactam antibiotics - Cephalosporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability ypropertiesp Stability to bacterial
More informationGeoffrey Coombs 1, Graeme Nimmo 2, Julie Pearson 1, Samantha Cramer 1 and Keryn Christiansen 1
Community Onset MRSA Infections in Australia: A Tale of Two Clones Geoffrey Coombs 1, Graeme Nimmo 2, Julie Pearson 1, Samantha Cramer 1 and Keryn Christiansen 1 Community Associated MRSA First isolated
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationCa-MRSA Update- Hand Infections. Washington Hand Society September 19, 2007
Ca-MRSA Update- Hand Infections Washington Hand Society September 19, 2007 Resistant Staph. Aureus Late 1940 s -50% S.Aureus resistant to PCN 1957-80/81 strain- of S.A. highly virulent and easily transmissible
More informationJCM Accepts, published online ahead of print on 2 July 2008 J. Clin. Microbiol. doi: /jcm
JCM Accepts, published online ahead of print on 2 July 2008 J. Clin. Microbiol. doi:10.1128/jcm.00265-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationTreatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals
Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationAntimicrobials & Resistance
Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 3 PURPOSE To assure that DOP inmates with Soft Tissue Infections are receiving high quality Primary Care for their infections and that the risk of infecting other inmates or staff is minimized.
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationDiagnosis: Presenting signs and Symptoms include:
PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective
More informationWhat Is Thought To Be The Problem?
Do We Need an Alternative Approach to the Management of Osteomyelitis? Jeffrey C. Karr DPM, CWS, ABLES, FAPWCA, FCCWS Founder, Central Florida Limb Salvage Alliance Chairman, Founder: The Osteomyelitis
More informationHEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE
Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationNEONATAL Point Prevalence Survey. Ward Form
Appendix 2 NEONATAL Point Prevalence Survey Ward Form Please fill in one form for each ward included in PPS Date of survey Person completing form (Auditor code) Hospital Name Department/Ward Neonatal departments
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationSUPPLEMENT ARTICLE. S114 CID 2001:32 (Suppl 2) Diekema et al.
SUPPLEMENT ARTICLE Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe,
More informationTACKLING THE MRSA EPIDEMIC
TACKLING THE MRSA EPIDEMIC Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine MRSA Trend (HA + CA) in US TSN Database USA (1993-2003) % of MRSA among S. aureus
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationPVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust
PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust Neonatal Case History Neonate born at 26 +2 gestation Spontaneous onset of
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationRESISTANCE, USE, INTERVENTIONS. Hugh Webb
RESISTANCE, USE, INTERVENTIONS Hugh Webb EU Initiatives: EARSS and ESAC. Antimicrobial Use and Resistance The Relationship. Bias and confounding in published studies. Mathematical modelling of resistance
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationOccurrence of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Srinagarind Hospital
Original Article Occurrence of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Srinagarind Hospital Aroonlug Lulitanond, M.Sc. 1,3 Aroonwadee Chanawong, Ph.D. 1,3
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationZyvox. Zyvox (linezolid) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.20 Subject: Zyvox Page: 1 of 7 Last Review Date: March 18, 2016 Zyvox Description Zyvox (linezolid)
More informationDalbavancin, enterococci, Gram-positive cocci, Latin America, staphylococci, streptococci
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01051.x Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres A. C. Gales 1, H. S. Sader 1,2
More informationMicrobiology : antimicrobial drugs. Sheet 11. Ali abualhija
Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis
More informationBrief Report THE DEVELOPMENT OF VANCOMYCIN RESISTANCE IN A PATIENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION
Brief Report THE DEVELOPMENT OF VANCOMYCIN RESISTANCE IN A PATIENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION KRZYSZTOF SIERADZKI, PH.D., RICHARD B. ROBERTS, M.D., STUART W. HABER, M.D.,
More informationCell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification
Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationEuropean Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004
European Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004 SECOND ANNUAL REPORT MJ Coyne 1, SJ Dancer 1, G Edwards 2, 3, D Morrison 2. 1 Health Protection Scotland, 2 Scottish MRSA
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationAntimicrobial agents
Bacteriology Antimicrobial agents Learning Outcomes: At the end of this lecture, the students should be able to: Identify mechanisms of action of antimicrobial Drugs Know and understand key concepts about
More informationInfections caused by Methicillin-Resistant Staphylococcus
MRSA infections are no longer limited to hospitals. An infectious disease specialist offers insight on what this means for dermatologists. By Robert S. Jones, DO, Reading, PA Infections caused by Methicillin-Resistant
More informationCell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017
Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationIn vitro Activity Evaluation of Telavancin against a Contemporary Worldwide Collection of Staphylococcus. aureus. Rodrigo E. Mendes, Ph.D.
AAC Accepts, published online ahead of print on 12 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00301-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationAntimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do?
Antimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do? John Ferguson, John Hunter Hospital, University of Newcastle, NSW, Australia Infectious Diseases
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationProtocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT
CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose
More information